Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · USD

$32.2

+0.22 (+0.7%)· Recorded snapshot

Market cap	5.6B
Net income (ttm)	-377.2M
EPS (ttm)	-$2.43
Shares out	173.6M
Volume	1,386,614
Beta	0.31

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -377.2M
EPS (ttm): -$2.43
Market cap: 5.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-109.7

P25 n/aP50 n/aP75 n/a

ROIC-49

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All COGT indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001622229
Company name	Cogent Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	19240Q201
Earnings date	2026-11-10
Earnings time	bmo
Employees	258
Employees change	53
Employees growth	25.85%
Enterprise value	$5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2018-03-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US19240Q2012
Last 10-K release date	2026-02-17
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2020-11-09
Last stock split type	Reverse
Market cap	$5.6B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$32.23
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	COGT
U.S. state	Massachusetts
Website	https://www.cogentbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-7.55%
FCF / EV yield	-6.24%
FCF yield	-5.62%
Forward EV/Sales	58.68x
Forward P/S	65.16x
P/B ratio	11.75x
Price / tangible book value	11.77x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.5M
ROA	-43.84%
ROA (5Y)	-36.66%
ROCE	-50.19%
ROE	-109.74%
ROE (5Y)	-68.01%
ROIC	-49.01%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.7M
Depreciation and amortization	$2.6M
EBIT	$-389.1M
EBITDA	$-386.5M
EPS	$-2.43
FCF per share	$-1.78
Financing cash flow	$861.5M
Free cash flow	$-309.2M
Free cash flow minus SBC	$-369.6M
Investing cash flow	$-500M
Net borrowing	$168.5M
Net cash flow	$54M
Net income	$-377.2M
Operating cash flow minus SBC	$-367.9M
Operating income	$-389.1M
Stock-based compensation	$60.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.72
Debt / equity	0.46
Interest coverage	-75.14
Long-term assets	$29.7M
Long-term liabilities	$242.9M
Net cash (debt)	$548M
Net cash / market cap	9.95%
Net cash growth	209.29%
Net debt / equity	-1.03
Piotroski F-Score	2
Property, plant and equipment	$27.4M
Shareholders' equity	$532.4M
Tangible book value	$467.6M
Tangible book value per share	$2.72
Total assets	$834.5M
Total cash	$792.3M
Total debt	$244.3M
Total liabilities	$302.2M
WACC	5.8%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$804.8M
Current liabilities	$59.3M
Current ratio	13.57
Net working capital	$-45.3M
Quick ratio	13.36
Working capital	$745.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-37.58%
Dividend yield	0%
Shareholder yield	-37.58%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$35.27
1D price change	0.69%
1M price change	-0.79%
1M total return	-0.79%
1W price change	2.61%
1W total return	2.61%
1Y price change	97.87%
1Y return CAGR	97.96%
1Y total return	97.87%
20-day SMA	$30.52
200-day SMA	$35.76
3M price change	-20.73%
3M total return	-20.73%
3Y price change	289.49%
3Y return CAGR	57.32%
3Y total return	289.49%
50-day SMA	$32.61
50-day SMA vs 200-day SMA	50under200
52-week high	$43.73
52-week high date	2025-12-08
52-week low	$13.78
52-week low date	2025-11-05
5Y price change	292.83%
5Y return CAGR	31.48%
5Y total return	292.83%
6M price change	-12.43%
6M total return	-12.43%
All-time high	$43.73
All-time high date	2025-12-08
All-time low	$3.67
All-time low date	2023-12-11
Average true range (ATR)	$1.25
Average volume	2.1M
Beta (1Y)	0.73
Beta (2Y)	0.98
Beta (5Y)	0.31
Change from 52-week high	-26.3%
Change from 52-week low	133.89%
Change from all-time high	-26.7%
Change from all-time low	773.43%
Change from open	1.07%
Day's gap	-0.37%
Dollar volume	$44.7M
High price	$32.62
Low price	$31.78
Monthly RSI	60.55
Open price	$31.89
Position in 52-week range	53.57%
Premarket change	0.13%
Premarket close	$32.01
Premarket price	$32.05
Premarket volume	830
Previous close	$32.01
Price vs 150-day SMA	-9.13%
Price vs 20-day SMA	5.05%
Price vs 200-day SMA	-10.35%
Price vs 50-day SMA	-1.69%
Relative volume	0.66
RSI	54.86
Sharpe ratio	0.91
Sharpe ratio (3Y)	0.81
Sharpe ratio (5Y)	0.65
Sortino ratio	3.81
Sortino ratio (3Y)	1.68
Sortino ratio (5Y)	1.31
Volume	1.4M
Weekly RSI	45.97
YTD price change	-9.76%
YTD total return	-9.76%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	172.6M
Float percentage	99.42%
Shares change (QoQ)	5.41%
Shares change (YoY)	37.58%
Shares held by insiders	0.56%
Shares held by institutions	117.69%
Shares outstanding	173.6M
Short % of float	11.28%
Short % of shares	11.21%
Short ratio	9.6 days

Deeper analysis on COGT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this COGT report

Is a complete COGT research report available?

No complete published report is available for Cogent Biosciences, Inc. (COGT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cogent Biosciences, Inc. (COGT)

Price

Financial snapshot

Fair-value bridge

Latest news · COGT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All COGT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on COGT

Frequently asked questions